15. Psammoma Body From: Indiana University Dept. of Pathology and Laboratory Medicine (erl.pathology.iupui.edu)
16. Staging for Epithelial Ovarian Cancer From: Cannistra S. N Engl J Med 2004;351:2519-2529 I - Ovaries II - Pelvic viscera III - Peritoneal implants, liver serosa, small bowel, omentum IV - Distant mets (liver parenchyma)
27. Phase III trials of intraperitoneal cisplatin/paclitaxel Alberts et al, NEJM 1996 Markman et al, JCO 2001 Armstrong et al, NEJM 2006 IV taxol + IP cis, IP taxol on d8 IV carbo x 2, IV taxol + IP cis IV cytoxan + IP cis Chemo-study 42% got 6 IP (41% ≤ 2 IP) IV:50 mo IP:66 mo (p=0.03) IV:18 mo IP:24 mo (p=0.05) IV taxol + IV cis Armstrong 18% ≤ 2 IP IV:52 mo IP:63 mo (p=0.05) IV:22 mo IP:28 mo (p=0.01) IV taxol + IV cis Markman 18% ≤ 2 IP IV:41 mo IP:49 mo (p=0.02) --- IV cytoxan + IV cis Alberts %receiving IP OS PFS Chemo-control Trial
28.
29.
30. Copyright restrictions may apply. Trimbos, J. B. et al. J. Natl. Cancer Inst. 2003 95:113-125. Copyright restrictions may apply. OS, optim. debulked OS, suboptim. debulked RFS, optim. debulked RFS, suboptim. debulked * *
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
Notas do Editor
PFS 16 mo for subopt. debulking/stage IV, 24 mo for opt. debulking